|
1.
|
Hazard LJ, Jensen RL and Shrieve DC: Role
of stereotactic radiosurgery in the treatment of brain metastases.
Am J Clin Oncol. 28:403–410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Chi A and Komaki R: Treatment of brain
metastasis from lung cancer. Cancers (Basel). 2:2100–2137. 2010.
View Article : Google Scholar
|
|
3.
|
Kim JE, Lee DH, Choi Y, et al: Epidermal
growth factor receptor tyrosine kinase inhibitors as a first-line
therapy for never-smokers with adenocarcinoma of the lung having
asymptomatic synchronous brain metastasis. Lung Cancer. 65:351–354.
2009. View Article : Google Scholar
|
|
4.
|
Porta R, Sánchez-Torres JM, Paz-Ares L, et
al: Brain metastases from lung cancer responding to erlotinib: the
importance of EGFR mutation. Eur Respir J. 37:624–631. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Hsiao SH, Lin HC, Chou YT, Lin SE, Kuo CC,
Yu MC and Chung CL: Impact of epidermal growth factor receptor
mutations on intracranial treatment response and survival after
brain metastases in lung adenocarcinoma patients. Lung Cancer.
81:455–461. 2013. View Article : Google Scholar
|
|
6.
|
Shih C, Chen VJ, Gossett LS, et al:
LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that
inhibits multiple folate-requiring enzymes. Cancer Res.
57:1116–1123. 1997.
|
|
7.
|
Bailon O, Chouahnia K, Augier A, et al:
Upfront association of carboplatin plus pemetrexed in patients with
brain metastases of lung adenocarcinoma. Neuro Oncol. 14:491–495.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Sigmond J, Backus HH, Wouters D, Temmink
OH, Jansen G and Peters GJ: Induction of resistance to the
multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon
cancer cells is associated with thymidylate synthase
overexpression. Biochem Pharmacol. 66:431–438. 2003. View Article : Google Scholar
|
|
9.
|
Spicer J and Harper P: Targeted therapies
for non-small cell lung cancer. Int J Clin Pract. 59:1055–1062.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ranson M, Reck M, Anthoney A, et al:
Erlotinib in combination with pemetrexed for patients with advanced
non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Ann Oncol. 21:2233–2239. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Minami S, Kijima T, Takahashi R, et al:
Combination chemo-therapy with intermittent erlotinib and
pemetrexed for pretreated patients with advanced non-small cell
lung cancer: a phase I dose-finding study. BMC Cancer. 12:2962012.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
13.
|
Liang Z, Zhang J, Zeng X, et al:
Relationship between EGFR expression, copy number and mutation in
lung adenocarcinomas. BMC Cancer. 10:3762010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Li C, Sun Y, Fang Z, et al: Comprehensive
analysis of epidermal growth factor receptor gene status in lung
adenocarcinoma. J Thorac Oncol. 6:1016–1021. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Orlando M, Lee JS, Yang C, Simms L and
Park K: Efficacy of pemetrexed-cisplatin (PC) in East Asian
patients (pts): Subgroup analysis of a phase III study comparing PC
versus gemcitabine-cisplatin (GC) in first-line treatment of
advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol.
27:80452009.
|
|
16.
|
Wu YL, Zhou C, Cheng Y, et al: Erlotinib
as second-line treatment in patients with advanced non-small-cell
lung cancer and asymptomatic brain metastases: a phase II study
(CTONG-0803). Ann Oncol. 24:993–999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Giovannetti E, Lemos C, Tekle C, et al:
Molecular mechanisms underlying the synergistic interaction of
erlotinib, an epidermal growth factor receptor tyrosine kinase
inhibitor, with the multi-targeted antifolate pemetrexed in
non-small-cell lung cancer cells. Mol Pharmacol. 73:1290–1300.
2008. View Article : Google Scholar
|
|
18.
|
Li T, Ling YH, Goldman ID and Perez-Soler
R: Schedule-dependent cytotoxic synergism of pemetrexed and
erlotinib in human non-small cell lung cancer cells. Clin Cancer
Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Van Schaeybroeck S, Karaiskou-McCaul A,
Kelly D, Longley D, Galligan L, VanCutsem E and Johnston P:
Epidermal growth factor receptor activity determines response of
colorectal cancer cells to gefitinib alone and in combination with
chemotherapy. Clin Cancer Res. 11:7480–7489. 2005.
|
|
20.
|
Magne N, Fischel JL, Dubreuil A, et al:
ZD1839 (Iressa) modifies the activity of key enzymes linked to
fluoropyrimidine activity: rational basis for a new combination
therapy with capecitabine. Clin Cancer Res. 9:4735–4742.
2003.PubMed/NCBI
|
|
21.
|
Budman DR, Soong R, Calabro A, Tai J and
Diasio R: Identification of potentially useful combinations of
epidermal growth factor receptor tyrosine kinase antagonists with
conventional cytotoxic agents using median effect analysis.
Anticancer Drugs. 17:921–928. 2006. View Article : Google Scholar
|
|
22.
|
Yatabe Y, Matsuo K and Mitsudomi T:
Heterogeneous distribution of EGFR mutations is extremely rare in
lung adenocarcinoma. J Clin Oncol. 29:2972–2977. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Henson JW, Ulmer S and Harris GJ: Brain
tumor imaging in clinical trials. AJNR Am J Neuroradiol.
29:419–424. 2008. View Article : Google Scholar
|
